The announcement of pivotal trial results is a critical event for a clinical-stage biopharmaceutical company like Mineralys Therapeutics. Positive results could lead to significant stock price appreciation due to increased investor confidence in the company's product pipeline and future revenue potential. Conversely, negative results could lead to a decline in stock price. Given the importance of these trials to the company's focus on hypertension treatments, the news is highly relevant and important for investors.